(Total Views: 582)
Posted On: 09/22/2019 7:43:24 AM
Post# of 154899
tonysd57@
"You and others are dead wrong on this one and grossly underestimate the investor appetite for biotech. I agree the company needs to hit a few milestones ( BLA submission, partnership, etc) and of course requires a cash infusion to clean up the balance sheet before they're even eligible to consider the move. Once on solid footing it would be huge mistake to continue trading on OTC. I'm hoping no later than Jan/Feb
Rarely a day goes by that I don't read in biotech/finance subscriptions of start ups/pre-clinical companies raking in millions of $$$$. Another case in point is IGM Biosciences here in California. They're just beginning pre-clincal studies on version of IgM antibodies to combat cancer.
Revenue is a pipe dream at this point but didn't stop them from raising $100 million+ in July in Series C financing and had an oversubscribed IPO this week that raised another $175 million! Out of the gate at $16 and jumped to $24--
It's criminal we're raising at .40cts -- Really a travesty considering how far along we are in trials and the tremendous versatility/utility PRO-140 demonstrates-- Two reasons;
1) Stuck on OTC
2) Terribly ineffective management/BOD when it comes to raising funds- Must not have the experience, pedigree or stability of a front office that would entice such lavish and wild spending"
"You and others are dead wrong on this one and grossly underestimate the investor appetite for biotech. I agree the company needs to hit a few milestones ( BLA submission, partnership, etc) and of course requires a cash infusion to clean up the balance sheet before they're even eligible to consider the move. Once on solid footing it would be huge mistake to continue trading on OTC. I'm hoping no later than Jan/Feb
Rarely a day goes by that I don't read in biotech/finance subscriptions of start ups/pre-clinical companies raking in millions of $$$$. Another case in point is IGM Biosciences here in California. They're just beginning pre-clincal studies on version of IgM antibodies to combat cancer.
Revenue is a pipe dream at this point but didn't stop them from raising $100 million+ in July in Series C financing and had an oversubscribed IPO this week that raised another $175 million! Out of the gate at $16 and jumped to $24--
It's criminal we're raising at .40cts -- Really a travesty considering how far along we are in trials and the tremendous versatility/utility PRO-140 demonstrates-- Two reasons;
1) Stuck on OTC
2) Terribly ineffective management/BOD when it comes to raising funds- Must not have the experience, pedigree or stability of a front office that would entice such lavish and wild spending"
(0)
(0)
